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Abstract
Background: The growth hormone secretagogue receptor (GHSR) is mediating hunger sensation when stimulated by its
natural ligand ghrelin. In the present study, we tested the hypothesis that common and rare variation in the GHSR locus are
related to increased prevalence of obesity and overweight among Whites.
Methodology/Principal Findings: In a population-based study sample of 15,854 unrelated, middle-aged Danes, seven
variants were genotyped to capture common variation in an 11 kbp region including GHSR. These were investigated for
their individual and haplotypic association with obesity. None of these analyses revealed consistent association with
measures of obesity. A -151C/T promoter mutation in the GHSR was found in two unrelated obese patients. One family
presented with complete co-segregation, but the other with incomplete co-segregation. The mutation resulted in an
increased transcriptional activity (p,0.02) and introduction of a specific binding for Sp-1-like nuclear extracts relative to the
wild type. The -151C/T mutation was genotyped in the 15,854 Danes with a minor allele frequency of 0.01%. No association
with obesity in carriers (mean BMI: 2764 kg/m
2) versus non-carriers (mean BMI: 2865 kg/m
2)( p .0.05) could be shown.
Conclusions/Significance: In a population-based study sample of 15,854 Danes no association between GHSR genotypes
and measures of obesity and overweight was found. Also, analyses of GHSR haplotypes lack consistent associations with
obesity related traits. A rare functional GHSR promoter mutation variant was identified, yet there was no consistent
relationship with obesity in neither family- nor population-based studies.
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Introduction
The growth hormone secretagogue receptor (GHSR) is a G-
protein coupled, seven-transmembrane receptor. It was an orphan
receptor until 1999 when its natural ligand, ghrelin, was identified
[1]. Ghrelin is a peptide hormone secreted from gastric cells in
response to absence of food in the stomach [1]. The ghrelin/
GHSR system has many functions. One of these is the signal
transduction of hunger by secretion of ghrelin from an empty
stomach, stimulating GHSR and leading to the sensation of
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10084hunger [2]. As a consequence, selectively knocking out the GHSR
in the arcuate nucleus in rodents results in lower body weight and
a decrease in adipose tissue [3]. In addition, a reduction in food
intake in mice receiving GHSR antagonists was observed [4].
Stimulation of hunger by the ghrelin/GHSR system is mediated
by neurons in the hypothalamic arcuate nucleus; in particular,
neurons expressing neuropeptide Y and agouti-related protein [5].
In fact, this effect of the ghrelin/GHSR system on hunger is
considered central for appetite regulation, as the GHSR has high
constitutive activity, which may be a set-point in appetite
regulation, counteracting the anorexigenic hormones leptin and
insulin [6].
The gene encoding GHSR, which is evolutionary highly
conserved, is located on chromosome 3q26, a region previously
showing linkage to measures of body composition [7]. A
comprehensive analysis of single nucleotide polymorphisms (SNPs)
and haplotype structure across the entire GHSR region (99.3 kb)
identified a linkage disequilibrium (LD) block consisting of five
SNPs showing linkage with body mass index (BMI) in an
intrafamilial segregation study among 178 obese pedigrees
(Whites), as well as association with obesity at the population
level among 1,418 Whites [8]. Common variants in GHSR were
also associated with obesity and obesity-related traits in a French
case-control study of 602 subjects; yet replication of such an
association in a German study sample of 888 individuals failed [9].
Furthermore, studies of the functional rare mutations, Ala20Glu
and Phe279leu, indicated a co-segregation with obesity [10,11].
In light of these previous findings, we investigated the effect of
seven common single nucleotide polymorphisms (SNPs) on obesity
at the population level. We also examined the effect of rare
variants by screening the promoter and coding regions of the
GHSR, and identified a rare gain-of-function mutation in the
GHSR promoter. The biochemical effect of this variant was
assessed in vitro and the physiological effect was investigated among
Danish and Czech individuals with a familial predisposition for
obesity and in a population-based study sample.
Methods
Study materials–population studies
The population of Danes used in this study were recruited from
the following study groups: 1) Inter99: 6,514 individuals from a
population-based randomised non-pharmacological intervention
study for prevention of cardiovascular disease conducted at the
Research Centre for Prevention and Health in Copenhagen
County (ClinicalTrials.gov ID-no:NCT00289237 [12]). 2) SDC:
676 unrelated middle-aged individuals from a population based
sample recruited at Steno Diabetes Center. 3) Addition: 8,664
individuals from a high-risk screening study for type 2 diabetes
recruited from Department of General Practice at the University
of Aarhus, Aarhus, Denmark (ClinicalTrials.gov Identifier:
NCT00237548 [13]). Cases were defined as having a BMI above
30 kg/m
2 and controls as having a BMI below 25 kg/m
2. Of the
4,217 individuals having a BMI above 30 kg/m
2 1,136 were from
study group 1, 175 were from study group 2 and 2,906 were from
study group 3. Of the 3,217 individuals having a BMI below
25 kg/m
2 2,831 were recruited from study group 1 and 386 were
from study group 2. Individuals from study group 3 with a BMI
below 25 kg/m
2 were excluded from the case-control studies as
this study group 3 was collected based on a high risk of having or
developing type 2 diabetes, thus even people who were lean are
not likely to be representative of the general population of lean
control individuals. All study participants were Danes by self-
report.
Mutation screening
82 obese probands with a mean BMI of 35.56 standard
deviation (SD) of 4.6 kg/m
2 were selected from families with a
least two overweight individuals recruited at the outpatient clinic
at Steno Diabetes Center. 28 (7 men/21 women) lean subjects
with a BMI of 20.061.7 kg/m
2 were from study group 2.
Mutation identification was performed using single-strand confor-
mation polymorphism of the coding region (including intron-exon
boundaries) along with 378 base pairs of the minimal promoter
relative to the ATG site of GHSR (NCBI accession number:
AY322544 and AF369786) on DNA from Danish probands.
Primers and conditions are available by request to corresponding
author.
Screening for the -151C/T GHSR variant was also performed in
289 (157 girls/132 boys) unrelated obese Czech children, aged 1–
18 years by PCR-RFLP. Inclusion criteria were obesity-onset
before the age of 11 years and BMI above the 97
th percentile for
sex and age according to Czech national references [14]. The
average age of obesity-onset was 4.963.1 years and the average Z-
score for BMI at the time of recruitment was 4.361.7. MC4R
mutations in the -151C/T GHSR variant carriers as a cause of
obesity were excluded by sequencing.
Family studies
Family members of the Danish and of the Czech probands
carrying the GHSR -151 C/T promoter mutation were examined
for the presence of this variant using sequencing.
Ethics statement
Informed written consent was obtained from all participants (or
legal guardian if under 18 years) and the study protocols were
approved by the Ethics Committee of the 3rd Faculty of Medicine,
Charles University in Prague or the regional Ethics Committees in
Denmark (ethics committee, Copenhagen County for the Inter99
and the SDC and ethics committee, Aarhus County for the
Addition) and the study was conducted in accordance with the
Helsinki declaration II.
Anthropometrics, behavior and biochemical assays
Population studies. Height and weight were measured in
light indoor clothes and without shoes, and BMI was calculated as
weight (kg)/(height (m))
2. Blood samples for biochemical analyses
were drawn in the morning after an overnight fast. Plasma glucose
and serum specific insulin (and intact proinsulin) were analysed
using Steno Diabetes Center standard methods [12]. Serum total
and HDL cholesterol were analysed using enzymatic colorimetric
methods (GPO-PAP and CHOD-PAP, Roche Molecular
Biochemicals, Germany).
Family studies. Height and weight were measured as
described above. After a minimum 12 hour fast, carriers of the -
151C/T mutation were examined for circulating levels of fasting
glucose, triglycerides, total cholesterol, free fatty acids, leptin,
luteinizing hormone (LH), follicle stimulating hormone (FSH),
growth hormone, IGF-1 and IGF-BP3 by standard methods at the
Institute for Human Nutrition, Copenhagen, Denmark or the
Department of Paediatrics and Centre for Research of Diabetes,
Metabolism and Nutrition, 3rd Faculty of Medicine, Charles
University, Prague, Czech Republic. The habitual eating behavior
of the subjects was assessed by use of a three-factor eating
questionnaire (TFEQ), which measured dietary restraint,
disinhibition and hunger [15]. A meal test was conducted in
three Danish family members, DK-III-2, DK-II-2 and DK-IV-1.
The breakfast was given after an overnight fast and spontaneous
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4.5 hours later. The breakfast had a fixed size and energy content,
consisting of yogurt, bread, butter, cheese, jam, kiwi-fruit, orange
juice and water with a total energy content equivalent to 20% of
each subject’s 24 hours energy requirement [16]. The lunch
consisted of pasta, minced beef, sweet corn, carrots, green peppers,
onions, courgettes and cream. The distribution of energy in both
meals was 50 energy-percent (E%) carbohydrates, 37 E% fat and
13 E% protein. Subjects had followed a weight-maintaining
standardised diet containing the same energy distribution two days
prior to the test day. The energy and nutrient composition of the
test meals and diets were calculated using the DANKOST 2
program, based on the Danish food composition tables [17]. Food
items were prepared at the Department of Human Nutrition.
Genotyping
Common SNPs needed to capture the locus variation in a
region including 2 kb upstream and 5.5 kb downstream of GHSR
(approx. 11 kb) were selected using pair wise tagging of SNPs with
a minor allele frequency (MAF) .0.05 with R
2.0.8. The SNPs
selected were: rs1403637, rs1916345, rs2948694, rs572169,
rs2922126, rs495225, rs509035. These SNPs and the -151C/T
promoter variant were genotyped using chip-based matrix-assisted
laser desorption/ionisation time-of-flight mass spectrometry (DNA
Mass-ARRAY; Sequenom, San Diego, CA) of PCR-generated
primer extension products as described earlier [18] or using
Taqman allelic discrimination (KBioscience, Hoddesdon, UK). All
genotypes were in Hardy-Weinberg equilibrium (p.0.08). The
genotypic success of GHSR tag SNPs was above 95.5% with a
mismatch frequency below 0.3%. The GHSR -151C/T variant
had a genotype success rate of 92.6% and an error rate of 0.2%.
In vitro analysis of the GHRS -151C.T mutation
Two constructs with the promoter segment spanning from
2643 to 21 bp with and without the mutation (referred to as 643-
Mutant and 643-Wild type) were prepared by amplification of
DNA from one carrier and one non-carrier of the -151C.T
mutation. Subsequently, introduction of BglII and HindIII sites
(New England Biolabs) and site-directed mutagenesis was followed
by digestion and ligation of those sites to a pGL3 Basic Vector
(Promega). After ligation all constructs were bidirectionally
sequenced (MWG-biotech). Primers, restriction-enzyme-cleavage-
site-generating-primers and PCR conditions are available on
request from the corresponding author.
Rat mammosomatotrophic pituitary tumor cell lines, GH1
(ATCC) and GH4 (ATCC), were maintained in DMEM 1885
with 10% FBS, 1% glutamine and 1% penicillin-streptomycin. The
ghrelin-receptor-promoter-pGL3 constructs, pGL3-Basic Vector
(Promega) and pGL3-Promoter Vector (Promega) were transfected
into the GH1 and GH4 cells. The constructs were co-transfected
with CMV-Renilla Control Vector (Promega). Cells were trans-
fected with 50 ng luciferase construct and 50 ng renilla construct in
wells with 50,000 (GH1) and 40,000 (GH4) cells, respectively. The
luciferase/renilla assay was performed using Firelite dual lumines-
cence reporter gene assay system Kit (PerkinElmer) according to
manufacture’s protocol. Luciferase activity of each construct was
normalised with the correspondent renilla activity, and values were
expressed relative to the activity of the basic construct. The
experiments were repeated 4 times and each experiment represents
the mean of 6 replicates. Electro mobility shift assays (EMSAs) were
performed with nuclear extracts from GH4 cells incubated with
labeled oligonucleotide probes containing a Sp1 consensus site, the
wild type GHSR 2151C or the mutated GHSR 2151T sequence.
Anti-Sp1 antibody was added to the reaction mix. The binding to
the 2151T probe was competed with 200-fold molar excess of
unlabeled probe.
Statistical analyses
Fisher’s exact test and logistic regression were applied to test for
significant differences in allele frequencies and genotype distribu-
tion in the obesity case-control studies adjusted for age and sex. A
multiple linear model was used to test for difference between
genotype groups assuming an additive model in quantitative trait
studies. The genotype-quantitative trait study was performed after
excluding patients with known type 2 diabetes (Jørgensen et al,
2003). In the present study population a high LD (R
2=0.96)
between rs509035 and rs572169 was observed and data for
rs509035 are therefore not shown (Figure S1).
An expectation-maximisation (EM) algorithm was applied to
estimate the haplotype frequencies used in the association studies.
The global p-value is an estimate of the overall effect of haplotypes
in the statistical model and the specific p-value is an estimate of the
effect of a specific haplotype compared to the effect of the
remaining haplotypes combined [19]. Haplotypes with a frequen-
cy below 5% were excluded.
Analyses were performed using Statistical Package for Social
Science (SPSS, Chicago, Ill., USA) version 12.0 and RGui version
2.7.0 except for analyses of the activity difference between mutant
and wild type constructs which was calculated using a t-test for
paired samples. A p-value of less than 0.05 was considered
significant.
Results
HapMap-based population studies of common GHSR
variants
To clarify if common variations in GHSR associate with obesity
in a Danish study population we genotyped seven SNPs in GHSR
including a region of 11 kbp (HapMap build 35; region:
173640000–173651000 bp). None of the SNPs were associated
with obesity (Table S1) or related quantitative traits (BMI, weight,
waist circumference and waist-to-hip ratio) (Table 1).
Four haplotypes were constructed from six of the variations
located within the same LD block (Figure S1). A trend on global
association was seen for waist-to-hip ratio (p=0.06), without
evidenceforanyspecifichaplotypecausingtheassociation(Table2).
Mutation screening for rare GHSR variants
To discover potential rare variants we performed a mutational
analysis of the coding region and the minimal promoter of GHSR.
We identified six variants, of which five were known synonymous
variants: Asp20Asp (rs2232165, minor allele frequency (MAF):
2.1%), Glu57Glu (rs495225, MAF: 24.1%), Leu149Leu
(rs2232169, MAF: 2.6%), Arg159Arg (rs572169, MAF: 34.3%),
Pro177Pro (rs4988509, MAF: 0.7%). These synonymous variants
were not further investigated. The remaining variant was a rare
mutation located in the promoter region (2151 C/T) and the
mutation was identified in one obese individual.
Family studies of the 2151 C/T promoter mutation
This -151 C/T promoter variant co-segregated with age-
adjusted overweight or obesity in a Danish pedigree (Figure 1).
The index patient, her son, and sister had all been overweight or
obese since the onset of puberty and her mother since her early
twenties. The index patient had type 2 diabetes and her sister had
impaired glucose tolerance.
In 289 obese Czech children, we identified an additional
heterozygous carrier of the -151C/T mutation and co-segregation
Genetic Variation in the GHSR
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Wild type Heterozygous Homozygous PADD
-151 promoter variant
N( M / W ) 14271(7473/6798) 26(17/9) - -
Age (years) 54610 5569- -
BMI (kg/m
2) 27.564.9 26.563.8 - 0.2*
Weight (kg) 81.1616.3 79.1614.6 - 0.2*
Waist (cm) 92.6614.3 92.3612.0 - 0.4*
Waist-to-hip ratio 0.8660.09 0.8860.08 - 0.6*
Rs1403637
N( M / W ) 5768(3039/2729) 6947(3645/3302) 2190(1149/1041)
Age (years) 54.569.9 54.5610.0 54.469.9
BMI (kg/m
2) 27.664.8 27.664.9 27.564.9 0.7
Weight (kg) 81.1616.2 81.0616.3 81.0616.3 0.8
Waist (cm) 92.6614.3 92.6614.4 92.4614.1 0.9
Waist-to-hip ratio 0.8660.09 0.8660.09 0.8660.09 0.2
Rs1916345
N( M / W ) 10205(5351/4854) 4107(2124/1983) 451(269/182)
Age (years) 54.469.9 54.8610.0 54.669.8
BMI (kg/m
2) 27.564.8 27.664.9 27.865 0.6
Weight (kg) 81.1616.3 80.7616 82.6616.5 0.7
Waist (cm) 92.5614.2 92.5614.3 94.3614.2 0.5
Waist-to-hip ratio 0.8660.09 0.8660.09 0.8860.09 0.8
Rs2948694
N( M / W ) 11844(6242/5602) 2722(1407/1315) 189(93/96)
Age (years) 54.669.9 54.2610 54.7610.2
BMI (kg/m
2) 27.664.9 27.564.8 28.064.8 0.6
Weight (kg) 81.1616.2 81616.4 81.9616.4 0.5
Waist (cm) 92.6614.3 92.5614.4 93.3614.8 0.4
Waist-to-hip ratio 0.8660.09 0.8660.09 0.8560.08 0.4
Rs572169
N( M / W ) 6535(3412/3123) 6444(3406/3038) 1630(848/782)
Age (years) 54.669.9 54.5610 54.669.6
BMI (kg/m
2) 27.664.9 27.664.9 27.664.8 0.9
Weight (kg) 80.9616.3 81.3616.2 81.2616.5 0.3
Waist (cm) 92.6614.3 92.8614.3 92.4614.2 0.7
Waist-to-hip ratio 0.8660.09 0.8660.09 0.8660.09 0.1
Rs495225
N( M / W ) 7791(4109/3682) 5845(3045/2800) 1174(621/553)
Age (years) 54.469.9 54.5610 54.569.8
BMI (kg/m
2) 27.664.8 27.564.9 27.864.8 0.3
Weight (kg) 81.2616.3 80.8616.2 81.8616.4 0.9
Waist (cm) 92.5614.2 92.4614.3 93.3614.6 0.2
Waist-to-hip ratio 0.8660.09 0.8660.09 0.8660.09 0.8
Rs2922126
N( M / W ) 6587(3485/3102) 6431(3374/3057) 1626(825/801)
Age (years) 54.669.8 54.3610 54.569.9
BMI (kg/m
2) 27.664.8 27.664.9 27.464.8 0.6
Weight (kg) 81616.2 81.2616.3 80.5616.2 0.9
Waist (cm) 92.5614.2 92.7614.4 92.1614.3 0.7
Waist-to-hip ratio 0.8660.09 0.8660.09 0.8660.09 0.4
Data represents means 6 SD. P-values were calculated using general linear model with age and sex as covariates. Subjects already diagnosed with type 2 diabetes at
time of examination were excluded from the analyses. PADD, p-values for additive analyses adjusted for sex and age. *Dominant model.
doi:10.1371/journal.pone.0010084.t001
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The children CZ-III-2 and CZ-III-4 (Figure 2) were also carriers
of the mutation with BMIs of 22.0 (Z-score: +0.04) and 21.1 (Z-
score: +0.3) kg/m
2, respectively, which is above the age and sex-
adjusted 50
th percentile. When linkage analysis was performed in
the Danish and Czech pedigrees they showed a LOD score for
obesity at the GHSR locus of Z =1.7.
In vitro analysis of the GHRS -151C.T mutation
Studies of the transcriptional activity of the -151T promoter
compared to a wild type showed an increased transcriptional
activity measured as renilla-controlled luciferase activity in
constructs expressing the 643 nucleotides upstream of the
translation initiation site (Figure 3). In silico analyses predicted a
change in the binding of several transcription factors including the
introduction of a Sp1-like binding site caused by the introduction of
the -151 variant. Electro-mobility shift assays (EMSAs) showed that
the -151T mutant sequence created a high affinity binding site for a
nuclearcomplexdisplacedbyanti-Sp1antibodyandbycompetition
with an Sp1 consensus oligonucleotides (Figure 4). Displacement of
the labelled mutant probe was not observed with an unrelated
antiserum or unlabeled Egr1 and Ets1 probes (data not shown).
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Figure 1. Pedigree of Danish family carrying the 2151 GHSR
promoter variant. Filled symbols indicate obese subjects. For
subjects aged 18 years or older, obesity was defined as a BMI
$30 kg/m
2, for children international cut off points for obesity were
used to define obesity (Cole, Bellizzi, et al. 2000 428/id). The index
patient is indicated by the arrow. The roman number refers to
generation and the text below each individual represents the following:
family-specific identification number; genotype NN, no mutation; NM,
heterozygous GHSR 2151C.T mutation and age (years)/maximal BMI
(kg/m
2). DK-III-3 was not available for medical exams or interviews for
this study. DK-X-Y (Danish family, generation X and person ID Y). The
index patient (DK-III-2).
doi:10.1371/journal.pone.0010084.g001
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anthropometrics, biochemical variables and health
behavior
Due to the established functionality of the -151T GHSR
mutation the physiological and biochemical profile of carriers of
the -151T transcription-activating mutation was examined in the
Danish and Czech families. Using the TFEQ we did not see
consistent measures of hunger, restrain or disinhibition for carriers
of the -151T mutation (Table S2). Also, birth weight and height as
well as psychosocial and intellectual development were assessed as
being normal by self-report of mutation carriers. None of the
selected biochemical measures for family members were abnormal
(Table S3). Neither the meal test revealed an abnormal response
(data not shown).
Search for potential impact of the -151 promoter
mutation at the population level
Despite the lack of consistent linkage with obesity of the -151
promoter mutation in the investigated families, we examined the
possible association of the variant with obesity in the general
population. Due to the low allele frequency only 26 heterozygous
and no homozygous individuals were identified (Table 3).
Applying a dominant model of inheritance we found no
association between mutation carriers and prevalence of obesity
(Table 3) or quantitative measures of body fat (Table 1).
When evaluating these results it should, however, be kept in
mind that no correction for multiple testing was made.
Discussion
Haplotypes composed of common variants within the GHSR
locus showed borderline association with waist-to-hip ratio, despite
Figure 2. Pedigree of Czech family carrying the -151 GHSR promoter variant. Filled symbols indicate obese subjects. For subjects above 18
years obesity was defined as a BMI $30 kg/m
2, obesity in children was defined as a BMI above 97th percentile for sex and age according to the Czech
national references (27). The index patient is indicated by the arrow. The roman number refers to the generation and the text below each individual
represents the following: family-specific identification number; genotype NN, no mutation; NM, heterozygous GHSR -151C.T mutation and age
(years)/maximal BMI (kg/m
2). All persons are represented with their maximal BMI and age at maximal BMI. CZ-X-Y (Czech family, generation X and
person ID Y). CZ-II-3 has not been available for a medical exam or interview, but is reported by family members to be lean.
doi:10.1371/journal.pone.0010084.g002
Figure 3. Transcriptional activity of the 2151 wild type (C) and
the variant (T) GHSR promoter. Activity of GHSR –151T versus
2151C 2643/pGL3 GHSR gene constructs in GH1 and GH4 cells. Values
represent the mean 6 SD of at least 3 measurements of luciferase
activity normalised with CMV-renilla activity expressed as fold induction
relative to the activity of the wild type promoter. P values: * p=0.0005
and ** p=0.02, calculated by t-test for independent samples.
doi:10.1371/journal.pone.0010084.g003
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individual variants. GHSR haplotypes have previously been
associated with obesity [8], yet the only overlapping variant in
these haplotype studies was rs572169. This variant has previously
been found to associate with obesity on its own [8,9]. However, in
line with our findings, this could not be replicated in a German
study sample. Thus, common GHSR variants are most likely not
major contributors to obesity among Caucasian individuals.
Previous studies have implied not only an effect of common
GHSR variants on the pathogenesis of obesity but also of rare
variants [10]. From the mutation screening the mostly likely
functional variant identified was the -151C/T mutation located in
the GHSR promoter. It was further investigated in two families (a
Danish and Czech). Whilst we found complete co-segregation with
obesity or overweight within the Danish family, only incomplete
co-segregation was demonstrated within the Czech family possibly
due to incomplete penetrance of the variant. The mutation
increased the transcriptional activity of GHSR. This increase is
probably due to an introduction of a highly specific SP-1-like site
as we have shown that other candidate consensus sequences, such
as Egr1 and Ets1, predicted to bind selectively to the -151T
mutant promoter by our in silico analyses did not bind.
The increased GHSR transcriptional activity and thereby the
increased expression of GHSR would be expected to lead to
increased signaling independent of the ghrelin hormone due to the
high constitutive activity of this receptor, resulting in a possible
increase in appetite and decrease in energy expenditure. Therefore,
changes in GHSR expression could play a major role in appetite
regulation and energy expenditure as seen in the Danish pedigree.
Yet, this hypothesis was not supported by the outcome of TFEQ.
Despite the functionality of the -151C/T GHSR mutation we
did not find a significant impact of this mutation in the general
Figure 4. Effect of the GHSR -151T variant on the affinity of the Sp1-binding site by EMSAs. GH4 nuclear extracts incubated with labeled
oligonucleotide probes containing an SP1 consensus site, the wild type GHSR -151C sequence, or the mutated GHSR –151T sequence. A: anti SP1
antibody (a-SP1) was added to the reaction mix. B: binding to the –151T probe was competed with 200-fold molar excess of indicated unlabeled
competitor probes. An arrow points to the complex exhibiting sequence-selective binding to the –151T probe. C: Sequences of wild type and mutant
oligonucleotide probes.
doi:10.1371/journal.pone.0010084.g004
Table 3. Obesity case-control study of the 2151 C/T GHSR promoter variant in Danes from the Inter99 study, the Danish
ADDITION Screening Study and the Steno Diabetes Center.
BMI ,25 kg/m
2 BMI 25 $,30 kg/m
2 BMI $30 kg/m
2 PFishers (dom) OR (CI) PGLM (dom)
CC 2855 (99.9) 6086 (99.9) 3852 (99.9)
CT 4 (0.1) 14 (0.1) 5 (0.1)
TT 0 0 0
MAF 0.1 (0.0–0.1) 0.1 (0.1–0.2) 0.1 (0.0–0.1) 1.0 0.93 (0.2–4.67) -
GC - 0.61 (0.14–2.58) 0.5
Data are number of subjects with each genotype (% of each group). PFishers: Fisher’s exact test comparing allele frequencies and genotype distribution between lean
(BMI ,25 kg/m
2) and obese (BMI $30 kg/m
2) subjects. PGLM: General linear model (GLM) adjusted for sex and age comparing differences in genotype distribution
Genotype distribution (GD). Minor allele frequency (MAF). OR: is the increased risk pr. allele of being obese. Only analyses assuming a dominant model (dom) have been
performed due to the low allele frequency. BMI, body mass index.
doi:10.1371/journal.pone.0010084.t003
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carriers. Whilst, it can not be ruled out that this rare GHSR
promoter variant may contribute modestly to the pathogenesis of
obesity it would require a much larger study sample to investigate
this.
In summary, common variants in GHSR did not associate with
measures of obesity or overweight in the general population of
Danes. However, a rare promoter variant, which exerts a
significant functional effect on the ghrelin receptor transcription,
showed partial co-segregation with obesity and overweight when
examined in 2 pedigrees of whites.
The study is part of the DanORC project (http://www.danorc.
dk) and was additionally supported by the University of
Copenhagen, the Danish Diabetes Association, The European
Union (HEPADIP, grant no. LSHM-CT-2005-018734), the
Danish Medical Research Council, the Danish Agency for Science
Technology and Innovation (grant no. 271-06-0539), the Czech
research project of MSM No. 0021620814 and an European
Society of Paediatric Endocrinology (ESPE) research fellowship
sponsored by Novo Nordisk.
Supporting Information
Figure S1 LD structure of common variants genotyped in the
GHSR locus. A; D’ value. B; R
2 value. Black bar is marking the
LD-block located in the region tagged by variants.
Found at: doi:10.1371/journal.pone.0010084.s001 (5.95 MB
TIF)
Table S1 Association of variants in GHSR among Danish study
participants recruited from the Inter99 study, the Danish
ADDITION Screening Study and the Steno Diabetes Center.
Data are number of subjects with each genotype (% of each
group). PFishers: Fisher’s exact test comparing allele frequencies and
genotype distribution between lean (BMI ,25 kg/m
2) and obese
(BMI $30 kg/m
2) subjects. PGLM: General linear model (GLM)
adjusted for sex and age comparing differences in genotype
distribution Genotype distribution (GD). Minor allele frequency
(MAF). OR: is the increased risk pr. allele of being obese.
Found at: doi:10.1371/journal.pone.0010084.s002 (0.10 MB
DOC)
Table S2 Three Factor Eating Questionnaire (TFEQ) values
from the Danish and Czech family members. DK-X-Y (Danish
family, generation X and person ID Y). CZ-X-Y (Czech family,
generation X and person ID Y).W, woman, M, man, nd= not
determined. Maximum scores: Restraint =21, Disinhibition =16,
and Hunger =14 (30).
Found at: doi:10.1371/journal.pone.0010084.s003 (0.06 MB
DOC)
Table S3 Biochemical variables from Danish and Czech
families. Luteinizing hormone (LH), follicle stimulating hormone
(FSH). DK-X-Y (Danish family, generation X and person ID Y).
CZ-X-Y (Czech family, generation X and person ID Y).
Found at: doi:10.1371/journal.pone.0010084.s004 (0.05 MB
DOC)
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